Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2103758 | 0.85 | BACE1 (0.47) | BACE1SLC6A4HRH3CYP1A2CYP2A6 | |
| SCHEMBL7988978 | 0.81 | GBA1 (0.41) | SLC6A4HRH3HSP90AB1 | |
| SCHEMBL21794980 | 0.79 | CES2 (0.40) | BACE1SLC6A4HRH3CYP1A2 | |
| SCHEMBL1753940 | 0.79 | KCNH2 (0.50) | BACE1HRH3TAAR1 | |
| SCHEMBL7974933 | 0.78 | TDP1 (0.51) | SLC6A4HRH3 | |
| SCHEMBL31307724 | 0.77 | RAB9A (0.55) | — | |
| SCHEMBL6240981 | 0.76 | CYP1A2 (0.65) | SLC6A4HRH3CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL29560700 | 0.76 | CYP1A2 (0.65) | SLC6A4HRH3CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL10740386 | 0.75 | LMNA (0.34) | HRH3 | |
| SCHEMBL5016452 | 0.75 | ALOX15 (0.48) | BACE1CYP1A2CYP2D6NFKB1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1990005531-A1 | METHOD FOR TREATING VASCULAR DISEASES | ABBOTT LABORATORIES (US) | 1990-05-31 | — | — | WO | disclosed |